Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alberto Hernando

Showing results (51-60 of 72) with videos related to

Pageof 8
Sort By:
Cancer Medicine|October 11, 2023
Selinexor for the treatment of recurrent or metastatic salivary gland tumors: Results from the GEMS-001 clinical trialAlberto Hernando-Calvo, Eoghan Malone, Daphne Day, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 8, 2026
Ficerafusp Alfa (BCA101) With Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Two-Year Results of an Expansion Cohort of a Phase I/Ib TrialGlenn J Hanna, Dan P Zandberg, Deborah J Wong, et al.
Oral Oncology|March 29, 2023
Nutritional status associates with immunotherapy clinical outcomes in recurrent or metastatic head and neck squamous cell carcinoma patientsAlberto Hernando-Calvo, Oriol Mirallas, David Marmolejo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 11, 2025
Phase I clinical trial of the bifunctional EGFR/TGF-β fusion protein ficerafusp alfa (BCA101) alone and in combination with pembrolizumab for advanced solid tumorsAlberto Hernando-Calvo, Richard D Carvajal, Paul K Paik, et al.
Journal for Immunotherapy of Cancer|December 21, 2025
Integrating C-reactive protein flare and early MRI dynamics for enhanced prediction of immunotherapy responseDaniel Navarro-Garcia, Francesco Grussu, Christina Zatse, et al.
Medrxiv : the Preprint Server for Health Sciences|December 3, 2020
Emergence and spread of a SARS-CoV-2 variant through Europe in the summer of 2020Emma B Hodcroft, Moira Zuber, Sarah Nadeau, et al.
Nature|June 7, 2021
Spread of a SARS-CoV-2 variant through Europe in the summer of 2020Emma B Hodcroft, Moira Zuber, Sarah Nadeau, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 8, 2026
Phase I trial of intravenous VCN-01 oncolytic adenovirus and durvalumab in patients with head and neck metastatic squamous cell carcinoma refractory to immunotherapyMaria Jove, Irene Braña, Marc Oliva, et al.
The Laryngoscope|August 26, 2025
Prognostic Factors in Sinonasal Cancers: A Multicenter Pooled AnalysisMilica Stefanovic, Alberto Hernando-Calvo, Jesus Brenes Castro, et al.
Eclinicalmedicine|February 21, 2024
Impact on costs and outcomes of multi-gene panel testing for advanced solid malignancies: a cost-consequence analysis using linked administrative dataAlberto Hernando-Calvo, Paul Nguyen, Philippe L Bedard, et al.
Pageof 8

Showing results (51-60 of 72) with videos related to

Sort By:
Pageof 8
Cancer Medicine|October 11, 2023
Selinexor for the treatment of recurrent or metastatic salivary gland tumors: Results from the GEMS-001 clinical trialAlberto Hernando-Calvo, Eoghan Malone, Daphne Day, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 8, 2026
Ficerafusp Alfa (BCA101) With Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Two-Year Results of an Expansion Cohort of a Phase I/Ib TrialGlenn J Hanna, Dan P Zandberg, Deborah J Wong, et al.
Oral Oncology|March 29, 2023
Nutritional status associates with immunotherapy clinical outcomes in recurrent or metastatic head and neck squamous cell carcinoma patientsAlberto Hernando-Calvo, Oriol Mirallas, David Marmolejo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 11, 2025
Phase I clinical trial of the bifunctional EGFR/TGF-β fusion protein ficerafusp alfa (BCA101) alone and in combination with pembrolizumab for advanced solid tumorsAlberto Hernando-Calvo, Richard D Carvajal, Paul K Paik, et al.
Journal for Immunotherapy of Cancer|December 21, 2025
Integrating C-reactive protein flare and early MRI dynamics for enhanced prediction of immunotherapy responseDaniel Navarro-Garcia, Francesco Grussu, Christina Zatse, et al.
Medrxiv : the Preprint Server for Health Sciences|December 3, 2020
Emergence and spread of a SARS-CoV-2 variant through Europe in the summer of 2020Emma B Hodcroft, Moira Zuber, Sarah Nadeau, et al.
Nature|June 7, 2021
Spread of a SARS-CoV-2 variant through Europe in the summer of 2020Emma B Hodcroft, Moira Zuber, Sarah Nadeau, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 8, 2026
Phase I trial of intravenous VCN-01 oncolytic adenovirus and durvalumab in patients with head and neck metastatic squamous cell carcinoma refractory to immunotherapyMaria Jove, Irene Braña, Marc Oliva, et al.
The Laryngoscope|August 26, 2025
Prognostic Factors in Sinonasal Cancers: A Multicenter Pooled AnalysisMilica Stefanovic, Alberto Hernando-Calvo, Jesus Brenes Castro, et al.
Eclinicalmedicine|February 21, 2024
Impact on costs and outcomes of multi-gene panel testing for advanced solid malignancies: a cost-consequence analysis using linked administrative dataAlberto Hernando-Calvo, Paul Nguyen, Philippe L Bedard, et al.
Pageof 8